Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Monika Abramiuk; Ilona Skrabalak; Malgorzata Satora; Marta Ostrowska-Leśko; Maja Joanna Czech; Julia Majchrzak; Marcin Bobiński

doi:10.12659/MSM.949526

28 August 2025 : Review article

Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Monika Abramiuk

^{AEFG 1*}, Ilona Skrabalak

^{EF 2}, Malgorzata Satora

^{AEF 3}, Marta Ostrowska-Leśko

^{AEFG 2}, Maja Joanna Czech^{EF 4}, Julia Majchrzak^{EF 4}, Marcin Bobiński

^{AFG 2}

DOI: 10.12659/MSM.949526

Med Sci Monit 2025; 31:e949526

Authors information Article notes Copyright and License information

Introduction Characteristics of Ovarian Cancer The Idea of Tailored Therapy Mechanisms of Action of Currently Used Agents Clinical Utilization of Targeted Treatments Upcoming Advances Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Antibody-drug conjugates(ADC) in EOC.

Target antigen	ADC	Drug intervention	Recruitment status	Phase	ClinicalTrials.gov ID	Publication
FRα	Mirvetuximab soravtansine	Mirvetuximab soravtansine + SL-172154	Enrolling by invitation	Ib	NCT05483933	–
	Mirvetuximab soravtansine	Mirvetuximab soravtansine + rucaparib	Active, not recruiting	I	NCT03552471	–
	Mirvetuximab soravtansine	Mirvetuximab soravtansine + gemcitabine hydrochloride	Completed	I	NCT02996825	–
	Mirvetuximab soravtansine	Carboplatin + mirvetuximab soravtansine	Recruiting	II	NCT04274426	–
	Mirvetuximab soravtansine	Carboplatin + mirvetuximab soravtansine	Recruiting	II	NCT04606914	–
	Mirvetuximab soravtansine	Carboplatin + mirvetuximab soravtansine	Recruiting	II	NCT05041257	–
	Mirvetuximab soravtansine	Carboplatin + mirvetuximab soravtansine	Recruiting	II	NCT05456685	–
	Mirvetuximab soravtansine	Mirvetuximab soravtansine	Active, not recruiting	III	NCT04209855	[–]⁹⁹
	Mirvetuximab soravtansine	Mirvetuximab soravtansine + bevacizumab	Recruiting	III	NCT05445778
	Luveltamab tazevibulin (STRO-002)	STRO-002	Recruiting	I	NCT03748186	–
	Luveltamab Tazevibulin (STRO-002)	STRO-002 + bevacizumab	Recruiting	I	NCT05200364	–
	Luveltamab tazevibulin (STRO-002)	STRO-002;STRO-002 + Pegfilgrastim;comparators	Recruiting	II/III	NCT05870748	–
	Farletuzumab ecteribulinm (MORAb-202)	Farletuzumab ecteribulin	Completed	I	NCT03386942	[]¹⁰²
	Farletuzumab ecteribulinm (MORAb-202)	Farletuzumab ecteribulin	Recruiting	I/II	NCT04300556	–
	Farletuzumab ecteribulinm (MORAb-202)	Farletuzumab ecteribulin	Recruiting	II	NCT05613088	–
	IMGN151	IMGN151	Recruiting	I	NCT05527184	–
	PRO1184	PRO1184	Recruiting	I/II	NCT05579366	–
	BAT8006	BAT8006 for Injection	Recruiting	I	NCT05378737	–
	Rinatabart sesutecan	Rina-S, Rina-S + carboplatinRina-S + bevacizumabRina-S + pembrolizumab		I/II	NCT05579366	–
HER2	Trastuzumab deruxtecan	Trastuzumab deruxtecan	Active, not recruiting	II	NCT04482309	–
	Trastuzumab duocarmazine (SYD985)	Trastuzumab duocarmazine + niraparib	Completed	I	NCT04235101	–
	Trastuzumab duocarmazine (SYD985)	Trastuzumab duocarmazine	Completed	II	NCT04205630	–
	A 166	A 166	Completed	I/II	NCT03602079	–
	SYD985	SYD985 + paclitaxel	Withdrawn	I	NCT04602117	–
MUC16	Sofituzumab vedotin (DMUC5754A)	DMUC5754A	Completed	I	NCT01335958	[]¹⁰⁷
Mesothelin	Anetumab ravtansine (BAY94-9343)	Anetumab ravtansine + pegylated liposomal doxorubicin	Completed	I	NCT02751918	–
	Anetumab ravtansine (BAY94-9343)	Anetumab ravtansine	Completed	I	NCT01439152	[]¹⁰⁶
	Anetumab ravtansine (BAY94-9343)	Anetumab ravtansine + bevacizumab	Active, not recruiting	II	NCT03587311	–
NaPi2b	Upifitamab Rilsodotin (XMT-1536)	Upifitamab rilsodotin + carboplatin	Terminated	I	NCT04907968	–
	Upifitamab Rilsodotin (XMT-1536)	Upifitamab rilsodotin	Active, not recruiting	Ib/II	NCT03319628	–
	Upifitamab Rilsodotin (XMT-1536)	Upifitamab rilsodotin	Terminated	III	NCT05329545	–
	lifastuzumab vedotin (DNIB0600A)	DNIB0600A	Completed	I	NCT01363947	–
	lifastuzumab vedotin (DNIB0600A)	Bevacizumab + Carboplatin + DNIB0600A, Carboplatin + DNIB0600A	Completed	I	NCT01995188	–
	lifastuzumab vedotin (DNIB0600A)	DNIB0600A	Terminated	II	NCT01991210	[]⁹⁸
	XMT-1592	XMT-1592	Terminated	Ib	NCT04396340	–
	TUB-040	TUB-040	Recruiting	I/II	NCT06303505	–
TROP2	SKB264	SKB264	Recruiting	I/II	NCT04152499	–
	SKB264	SKB264 + pembrolizumab	Recruiting	II	NCT05642780	–
	Datopotamab deruxtecan (Dato-DXd)	Dato-DXd, carboplatin + Dato-DXd + AZD5305	Recruiting	II	NCT05489211	–
Tissue factor	XB002	XB002	Recruiting	I	NCT04925284	–
Tissue factor	Tisotumab vedotin	Tisotumab vedotin	Completed	II	NCT03657043	–
Unknown	TORL-1-23	TORL-1-23	Recruiting	I	NCT05103683	–
Unknown	AZD5335	AZD5335, AZD5335 + AZD5305	Recruiting	I/IIa	NCT05797168	–
5T4	ASN004	ASN004	Active, not recruiting	I	NCT04410224	–
B7–H4	AZD8205	AZD8205	Recruiting	I/IIa	NCT05123482	[]¹⁰⁹
B7–H3	Vobramitamab duocarmazine	Vobramitamab duocarmazine + lorigerlimab	Recruiting	I	NCT05293496	–
AXL receptor tyrosine kinase	Enapotamab vedotin (HuMax-AXL-ADC)	Enapotamab vedotin	Completed	I/II	NCT02988817	–
CD166	CX-2009	CX-2009	Terminated	I/II	NCT03149549	–
TIM-1	CDX-014	CDX-014	Terminated	I	NCT02837991	[]¹¹⁰
Dipepti-dase 3	Tamrintamab pamozirine (SC-003)	SC-003, SC-003 + ABBV-181	Terminated	I	NCT02539719	[]¹⁰⁸
Lewis Y	SGN-15 (cBR96-doxorubicin immunoconjugate)	SGN-15 (cBR96-doxorubicin immunoconjugate) + gemcitabine	Terminated	II	NCT00051584	–
Cadherin-6	HKT228	HKT288	Terminated	I	NCT02947152	–
FRα – folate receptor-α; NaPi2b – type II sodium–phosphate cotransporter; TROP2 – trophoblast cell surface antigen 2; HER2 – human epidermal growth factor receptor 2; B7–H4 – B7 homolog 4; B7–H3 – B7 homolog 3; CD166 – cluster of differentiation 166; TIM-1 – transmembrane protein T-cell immunoglobulin mucin-1.

Back to the Article

Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Your Privacy